2. Search Result
Search Result
Results for "

memory+deficit

" in MedChemExpress (MCE) Product Catalog:

58

Inhibitors & Agonists

1

Biochemical Assay Reagents

3

Peptides

14

Natural
Products

7

Isotope-Labeled Compounds

1

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-10295
    SB 202190
    Maximum Cited Publications
    134 Publications Verification

    		 Organoid p38 MAPK Autophagy Apoptosis Neurological Disease Cancer
    SB 202190 is a selective p38 MAP kinase inhibitor with IC50s of 50 nM and 100 nM for p38α and p38β2, respectively. SB 202190 binds to the ATP pocket of the active recombinant human p38 kinase with a Kd of 38 nM. SB 202190 has anti-cancer activity and rescued memory deficits . SB202190 induces autophagy .
    SB 202190
  • HY-N6608
    Physostigmine
    2 Publications Verification

    Eserine

    		 Cholinesterase (ChE) Neurological Disease
    Physostigmine (Eserine) is a reversible acetylcholinesterase (AChE) inhibitor. Physostigmine can crosses the blood-brain barrier and stimulates central cholinergic neurotransmission. Physostigmine can reverse memory deficits in transgenic mice with Alzheimer's disease. Physostigmine is also an antidote for anticholinergic poisoning .
    Physostigmine
  • HY-B1266
    Physostigmine salicylate
    2 Publications Verification

    Eserine salicylate

    		 Cholinesterase (ChE) Neurological Disease
    Physostigmine salicylate (Eserine salicylate) is a reversible acetylcholinesterase (AChE) inhibitor. Physostigmine salicylate crosses the blood-brain barrier and stimulates central cholinergic neurotransmission. Physostigmine salicylate can reverse memory deficits in transgenic mice with Alzheimer's disease. Physostigmine salicylate is also an antidote for anticholinergic poisoning .
    Physostigmine salicylate
  • HY-W010892
    Scopolamine hydrobromide trihydrate
    Maximum Cited Publications
    21 Publications Verification

    Hyoscine hydrobromide trihydrate

    		 mAChR 5-HT Receptor Neurological Disease
    Scopolamine (Hyoscine) hydrobromide trihydrate is a high-affinity muscarinic antagonist that can cross the blood-brain barrier. Scopolamine hydrobromide trihydrate competitively antagonizes 5-HT3 receptors with an IC50 of 2.09 μM. Scopolamine hydrobromide trihydrate can induce cognitive and memory deficits in animals. Scopolamine hydrobromide trihydrate can be used in the research of preventing postoperative nausea and vomiting, motion sickness, nervous system diseases, etc .
    Scopolamine hydrobromide trihydrate
  • HY-N6967
    Levomenol

    (-)-α-Bisabolol

    		 Environmental Pollutants Apoptosis Neurological Disease Inflammation/Immunology
    Levomenol ((-)-α-Bisabolol), a monocyclic sesquiterpene alcohol, exerts antioxidant, anti-inflammatory, and anti-apoptotic activities. Levomenol also has neuroprotective effects and prevents neuronal damage and memory deficits through reduction of proinflammatory markers induced by permanent focal cerebral ischemia in mice. Levomenol attenuates nociceptive behaviour and central sensitisation in a rodent model of trigeminal neuropathic pain. Orally active .
    Levomenol
  • HY-N2736
    3′,4′,7-Trihydroxyflavone
    1 Publications Verification

    		 Beta-lactamase COX Interleukin Related Bacterial JNK ERK p38 MAPK STAT Apoptosis NO Synthase Nuclear Factor of activated T Cells (NFAT) Lactate Dehydrogenase Reactive Oxygen Species (ROS) SOD Akt Caspase Bcl-2 Family Infection Neurological Disease Inflammation/Immunology
    3′,4′,7-Trihydroxyflavone is an orally active inhibitor of OXA-48 (IC50 = 1.89 μM) and COX-1 (IC50 = 36.37 μM). 3′,4′,7-Trihydroxyflavone exhibits antioxidant and anti-inflammatory properties, inhibiting the release of inflammatory cytokines such as IL-6, IL-8, and TNF-α. 3′,4′,7-Trihydroxyflavone inhibits H2O2-induced neuronal apoptosis and ROS accumulation, and exerts anti-neuroinflammatory effects by suppressing the JNK-STAT1 pathway. 3′,4′,7-Trihydroxyflavone exhibits antimicrobial and antibiotic-modifying activities against multidrug-resistant Gram-negative enteric bacteria. 3′,4′,7-Trihydroxyflavone inhibits RANKL-induced osteoclast formation via NFATc1. 3′,4′,7-Trihydroxyflavone activates the CREB-BDNF axis and restores scopolamine (HY-N0296)-induced memory deficits in mice .
    3′,4′,7-Trihydroxyflavone
  • HY-N0541
    Pseudoginsenoside F11
    2 Publications Verification

    Ginsenoside A1

    		 Endogenous Metabolite Others
    Pseudoginsenoside F11 (Ginsenoside A1), a component of Panax quinquefolium (American ginseng), has been demonstrated to antagonize the learning and memory deficits induced by scopolamine, morphine and methamphetamine in mice.
    Pseudoginsenoside F11
  • HY-D0873
    HEPPS

    EPPS

    		 Amyloid-β Neurological Disease
    HEPPS (EPPS) is a buffering agent with the useful pH range from 7.3 ~ 8.7. HEPPS reduces Aβ-aggregate-induced memory deficits and rescues cognitive deficits in mice. EPPS is orally active and penetrates the blood-brain barrier .
    HEPPS
  • HY-17553
    Coluracetam
    3 Publications Verification

    MKC-231

    		 iGluR Neurological Disease
    Coluracetam (MKC-231) is an orally taken choline uptake enhancer. Coluracetam can improve the reduced acetylcholine levels in the hippocampus of rats and mice, enhancing learning difficulties, memory deficits, and cognitive impairments. Coluracetam induces a lower degree of hepatic venous hyperglycemia .
    Coluracetam
  • HY-W011978
    N-Acetyl-L-tryptophan

    		Endogenous Metabolite Mitochondrial Metabolism Neurokinin Receptor Caspase Interleukin Related Neurological Disease Inflammation/Immunology
    N-Acetyl-L-tryptophan is an antagonist of the neurokinin-1 receptor (NK-1R), disrupting the binding of substance P (SP) to NK-1R. This action provides neuroprotective effects, improving memory deficits and motor impairments. N-Acetyl-L-tryptophan is also an inhibitor of cytochrome c (Cytochrome c), and it exerts antioxidant and anti-inflammatory effects by inhibiting the expression of IL-1β and the activation of caspase-1. N-Acetyl-L-tryptophan holds promise for research in neurodegenerative and inflammatory diseases .
    N-Acetyl-L-tryptophan
  • HY-B2065
    Scopolamine hydrochloride
    Maximum Cited Publications
    21 Publications Verification

    (-)-Scopolamine hydrochloride; Hyoscine hydrochloride

    		 mAChR 5-HT Receptor Neurological Disease
    Scopolamine (Hyoscine) hydrochloride is a high-affinity muscarinic antagonist that can cross the blood-brain barrier. Scopolamine hydrochloride competitively antagonizes 5-HT3 receptors with an IC50 of 2.09 μM. Scopolamine hydrochloride can induce cognitive and memory deficits in animals. Scopolamine hydrochloride can be used in the research of preventing postoperative nausea and vomiting, motion sickness, nervous system diseases, etc .
    Scopolamine hydrochloride
  • HY-P2259
    TAT-GluA2 3Y
    2 Publications Verification

    		 iGluR Neurological Disease
    TAT-GluA2 3Y, an interference peptide, blocks long-term depression (LTD) at glutamatergic synapses by disrupting the endocytosis of AMPAR. TAT-GluA2 3Y can alleviate Pentobarbital-induced spatial memory deficits and synaptic depression .
    TAT-GluA2 3Y
  • HY-N2320
    Physostigmine hemisulfate
    2 Publications Verification

    Eserine hemisulfate

    		 Cholinesterase (ChE) Neurological Disease
    Physostigmine hemisulfate (Eserine hemisulfate) is a reversible acetylcholinesterase (AChE) inhibitor. Physostigmine hemisulfate can crosses the blood-brain barrier and stimulates central cholinergic neurotransmission. Physostigmine hemisulfate can reverse memory deficits in transgenic mice with Alzheimer's disease. Physostigmine hemisulfate is also an antidote for anticholinergic poisoning .
    Physostigmine hemisulfate
  • HY-120597
    SAK3

    		Calcium Channel Neurological Disease
    SAK3 is a potent T-type voltage-gated Ca 2+ channels (T-VGCCs) enhancer. SAK3 enhances Cav3.1 and Cav3.3 T-type Ca 2+ channel currents. Acute SAK3 administration improves memory deficits in olfactory-bulbectomized mice . SAK3 inhibits amyloid β plaque formation in APP-KI mice by activating the proteasome activity .
    SAK3
  • HY-120657
    9-PAHSA

    		CGRP Receptor NF-κB Neurological Disease Metabolic Disease Inflammation/Immunology
    9-PAHSA is an orally active endogenous GPR120 agonist (EC50=18 μM). 9-PAHSA significantly inhibits LPS-induced inflammatory responses by blocking the NF-κB pathway. 9-PAHSA induces adipocyte browning, enhances glucose uptake and reduces lipid accumulation, while improving mitochondrial function and the survival rate of steatotic hepatocytes. In terms of neuroprotection, 9-PAHSA regulates the expression of REST and BDNF in the prefrontal cortex of diabetic mice, and effectively prevents spatial working memory deficits and abnormal social behaviors. 9-PAHSA does not directly regulate insulin secretion or improve systemic insulin sensitivity, and possesses specific anti-inflammatory, metabolic regulatory and neuroprotective properties. 9-PAHSA can be used in the research of diabetes-related cognitive impairment, obesity and non-alcoholic fatty liver disease .
    9-PAHSA
  • HY-164288
    TDI-6570

    TDI-006570

    		 Cyclic GMP-AMP Synthase STING Neurological Disease Inflammation/Immunology
    TDI-6570 (TDI-006570) is a blood-brain barrier-permeable, orally active cGAS inhibitor with an IC50 of 1.64 μM. TDI-6570 exhibits high gastrointestinal absorption and a long brain half-life in mice, and shows no toxicity to primary neurons. By inhibiting the cGAS-STING-IFN signaling pathway, TDI-6570 reduces STING levels and the activation of TBK1, blocks double-stranded DNA-induced cGAS activation and downstream interferon-stimulated gene expression, thereby reducing tau protein spread and improving synaptic loss. TDI-6570 reverses memory deficits, increases the amplitude of long-term potentiation, enhances the MEF2C transcriptional network, restores PSD-95 and vGAT punctate structures, and significantly improves cognitive resilience. TDI-6570 can be applied to the research of Alzheimer's disease, Parkinson's disease, systemic lupus erythematosus, as well as various central nervous system and autoimmune diseases .
    TDI-6570
  • HY-109118A
    Masupirdine mesylate

    SUVN-502 mesylate

    		 5-HT Receptor Neurological Disease
    Masupirdine mesylate (SUVN-502 mesylate) is a potent, selective, orally active, and brain-penetrating 5-HT6 receptor antagonist (Ki of 2.04 nM for human 5-HT6 receptor). Masupirdine mesylate has pro-cognitive effects on all stages of cognition (acquisition, consolidation, and retention), and can reverse Scopolamine (HY-N0296), MK-801 (HY-15084B)-induced and aging-related memory deficits. Masupirdine mesylate can be used in the research of Alzheimer's disease .
    Masupirdine mesylate
  • HY-106432A
    Sabcomeline hydrochloride

    SB-202026 hydrochloride; Memric hydrochloride

    		 mAChR Dopamine Receptor Neurological Disease
    Sabcomeline (SB-202026; Memric) hydrochloride is a muscarinic receptor agonist capable of crossing the blood-brain barrier. Sabcomeline hydrochloride exhibits affinity for all hM1 to hM5 subtypes (pKi=6.72-7.23), and shows near-full agonism at the hM3 receptor, inducing extracellular acidification. Sabcomeline hydrochloride alters the binding kinetics of dopamine D2 receptors through neural network regulation. Sabcomeline hydrochloride also causes minimal cardiovascular changes, effectively reverses spatial memory deficits in rodents and induces conditioned taste aversion. Sabcomeline hydrochloride is an important tool compound in studies of Alzheimer's disease and related neurodegenerative diseases .
    Sabcomeline hydrochloride
  • HY-N0459
    3,5-O-Dicaffeoylquinic acid
    1 Publications Verification

    		 Others Neurological Disease
    3,5-O-Dicaffeoylquinic acid reverses Trimethyltin-induced learning and memory deficits .
    3,5-O-Dicaffeoylquinic acid
  • HY-W415004
    ACHE-IN-38

    		Cholinesterase (ChE) Neurological Disease
    ACHE-IN-38 (Compound mol-8) inhibits the metabolic breakdown of the neurotransmitter acetylcholine (ACh) by the enzyme acetylcholinesterase (AChE) and hence alleviates memory deficits in patients with Alzheimer’s Disease by potentiating cholinergic transmission .
    ACHE-IN-38
  • HY-115910A
    Y13g dihydrochloride

    		Interleukin Related Cholinesterase (ChE) Neurological Disease
    Y13g dihydrochloride is the potent inhibitor of both AChE and IL-6. Interleukin-6 (IL-6) and acetylcholinesterase (AChE) are two important targets implicated in progression of Alzheimer's Disease (AD). Y13g dihydrochloride reverses the STZ (HY-13753)-induced memory deficit, and shows histopathology similarly as in normal animals .
    Y13g dihydrochloride
  • HY-W770410
    9-PAHSA-13C4

    		Isotope-Labeled Compounds CGRP Receptor NF-κB Others
    9-PAHSA- 13C4 is 13C-labeled 9-PAHSA. 9-PAHSAis an orally active endogenous GPR120 agonist (EC50=18 μM). 9-PAHSAsignificantly inhibits LPS-induced inflammatory responses by blocking the NF-κB pathway. 9-PAHSAinduces adipocyte browning, enhances glucose uptake and reduces lipid accumulation, while improving mitochondrial function and the survival rate of steatotic hepatocytes. In terms of neuroprotection, 9-PAHSAregulates the expression of REST and BDNF in the prefrontal cortex of diabetic mice, and effectively prevents spatial working memory deficits and abnormal social behaviors. 9-PAHSAdoes not directly regulate insulin secretion or improve systemic insulin sensitivity, and possesses specific anti-inflammatory, metabolic regulatory and neuroprotective properties. 9-PAHSAcan be used in the research of diabetes-related cognitive impairment, obesity and non-alcoholic fatty liver disease .
    9-PAHSA-13C4
  • HY-N6608S
    Physostigmine-d3

    Eserine-d3

    		 Isotope-Labeled Compounds Cholinesterase (ChE) Neurological Disease
    Physostigmine-d3 is the deuterium labeled Physostigmine. Physostigmine (Eserine) is a reversible acetylcholinesterase (AChE) inhibitor. Physostigmine can crosses the blood-brain barrier and stimulates central cholinergic neurotransmission. Physostigmine can reverse memory deficits in transgenic mice with Alzheimer's disease. Physostigmine is also an antidote for anticholinergic poisoning .
    Physostigmine-d3
  • HY-175758
    AChE-IN-94

    		Cholinesterase (ChE) Amyloid-β Neurological Disease
    AChE-IN-94 is an orally active and blood-brain barrier penetrable AChE inhibitor with an IC50 of 0.40 μM and Ki of 0.28 μM. AChE-IN-94 prevents self-induced and AChE-mediated Aβ1-42 aggregation. AChE-IN-94 alleviates cognitive/memory deficits in Scopolamine (HY-N0296)-induced amnesic model. AChE-IN-94 can be used for the study of Alzheimer's disease (AD) .
    AChE-IN-94
  • HY-N6967R
    Levomenol (Standard)

    (-)-α-Bisabolol (Standard)

    		 Reference Standards Apoptosis Neurological Disease Inflammation/Immunology
    Levomenol (Standard) is the analytical standard of Levomenol. This product is intended for research and analytical applications. Levomenol ((-)-α-Bisabolol), a monocyclic sesquiterpene alcohol, exerts antioxidant, anti-inflammatory, and anti-apoptotic activities. Levomenol also has neuroprotective effects and prevents neuronal damage and memory deficits through reduction of proinflammatory markers induced by permanent focal cerebral ischemia in mice. Levomenol attenuates nociceptive behaviour and central sensitisation in a rodent model of trigeminal neuropathic pain. Orally active .
    Levomenol (Standard)
  • HY-W010892S
    Scopolamine-d3 hydrobromide

    Hyoscine-d3 hydrobromide

    		 Isotope-Labeled Compounds mAChR 5-HT Receptor Neurological Disease
    Scopolamine-d3 hydrobromide is the deuterium labeled Scopolamine hydrobromide (HY-B2065). Scopolamine (Hyoscine) hydrochloride is a high-affinity muscarinic antagonist that can cross the blood-brain barrier. Scopolamine hydrochloride competitively antagonizes 5-HT3 receptors with an IC50 of 2.09 μM. Scopolamine hydrochloride can induce cognitive and memory deficits in animals. Scopolamine hydrochloride can be used in the research of preventing postoperative nausea and vomiting, motion sickness, nervous system diseases, etc .
    Scopolamine-d3 hydrobromide
  • HY-179337
    PDE2-IN-1

    		Phosphodiesterase (PDE) PKA Neurological Disease
    PDE2-IN-1 is a potent and orally active PDE2 inhibitor with an IC50 of 0.6 μM, demonstrating neuroprotective effects. PDE2-IN-1 modulates the PKA/CREB/BDNF signaling pathway by inhibiting PDE2. PDE2-IN-1 improves memory deficits and cognitive impairment in an okadai acid (OKA)-induced Alzheimer’s disease (AD) mouse model. PDE2-IN-1 can be used for the research of AD .
    PDE2-IN-1
  • HY-W010892R
    Scopolamine hydrobromide trihydrate (Standard)

    Hyoscine hydrobromide trihydrate (Standard)

    		 mAChR Reference Standards 5-HT Receptor Neurological Disease
    Scopolamine hydrobromide trihydrate (Standard) is the analytical standard of Scopolamine hydrobromide trihydrate (HY-W010892). This product is intended for research and analytical applications. Scopolamine (Hyoscine) hydrobromide is a high-affinity muscarinic antagonist that can cross the blood-brain barrier. Scopolamine hydrobromide competitively antagonizes 5-HT3 receptors with an IC50 of 2.09 μM. Scopolamine hydrobromide can induce cognitive and memory deficits in animals. Scopolamine hydrobromide can be used in the research of preventing postoperative nausea and vomiting, motion sickness, nervous system diseases, etc .
    Scopolamine hydrobromide trihydrate (Standard)
  • HY-109118
    Masupirdine free base

    SUVN-502 free base

    		 5-HT Receptor Neurological Disease
    Masupirdine free base (SUVN-502 free base) is a potent, selective, orally active, and brain-penetrating 5-HT6 receptor antagonist (Ki of 2.04 nM for human 5-HT6 receptor). Masupirdine free base has pro-cognitive effects on all stages of cognition (acquisition, consolidation, and retention), and can reverse Scopolamine (HY-N0296), MK-801 (HY-15084B)-induced and aging-related memory deficits. Masupirdine free base can be used in the research of Alzheimer's disease .
    Masupirdine free base
  • HY-W011978S
    N-Acetyl-L-tryptophan-d3

    		Isotope-Labeled Compounds Endogenous Metabolite Mitochondrial Metabolism Neurokinin Receptor Caspase Interleukin Related Neurological Disease Inflammation/Immunology
    N-Acetyl-L-tryptophan-d3 is the deuterium labeled N-Acetyl-L-tryptophan (HY-W011978). N-Acetyl-L-tryptophan is an antagonist of the neurokinin-1 receptor (NK-1R), disrupting the binding of substance P (SP) to NK-1R. This action provides neuroprotective effects, improving memory deficits and motor impairments. N-Acetyl-L-tryptophan is also an inhibitor of cytochrome c (Cytochrome c), and it exerts antioxidant and anti-inflammatory effects by inhibiting the expression of IL-1β and the activation of caspase-1. N-Acetyl-L-tryptophan holds promise for research in neurodegenerative and inflammatory diseases .
    N-Acetyl-L-tryptophan-d3
  • HY-120657S
    9-PAHSA-d4

    		Isotope-Labeled Compounds CGRP Receptor NF-κB Others
    9-PAHSA-d4 is the deuterium labeled 9-PAHSA. 9-PAHSA is an orally active endogenous GPR120 agonist (EC50=18 μM). 9-PAHSA significantly inhibits LPS-induced inflammatory responses by blocking the NF-κB pathway. 9-PAHSA induces adipocyte browning, enhances glucose uptake and reduces lipid accumulation, while improving mitochondrial function and the survival rate of steatotic hepatocytes. In terms of neuroprotection, 9-PAHSA regulates the expression of REST and BDNF in the prefrontal cortex of diabetic mice, and effectively prevents spatial working memory deficits and abnormal social behaviors. 9-PAHSA does not directly regulate insulin secretion or improve systemic insulin sensitivity, and possesses specific anti-inflammatory, metabolic regulatory and neuroprotective properties. 9-PAHSA can be used in the research of diabetes-related cognitive impairment, obesity and non-alcoholic fatty liver disease .
    9-PAHSA-d4
  • HY-N8693
    Withanoside IV

    		COX Amyloid-β Sirtuin Reactive Oxygen Species (ROS) Apoptosis SARS-CoV Infection Neurological Disease
    Withanoside IV is an orally active, blood-brain barrier-permeable withanolide derivative. Withanoside IV specifically binds to the Sudlow I site of HSA, induces secondary structural changes in HSA, and forms stable HSA complexes. Withanoside IV inhibits the enzymatic activity of COX-2. Withanoside IV induces axonal regeneration, peripheral nervous system myelination and increased axonal density in spinal cord tissue, reduces reactive gliosis-related changes, and improves hindlimb motor function. Withanoside IV binds to amyloid-β 1-42 to inhibit its aggregation, induces neurite outgrowth and synapse reconstruction, repairs damaged axons and dendrites, enhances mitochondrial biogenesis, exerts neuroprotective effects via the BDNF and SIRT1 signaling pathways, reduces ROS production and neuronal apoptosis, and ameliorates memory deficits. Withanoside IV inhibits the activity of the SARS-CoV-2 main protease. Withanoside IV can be used in research related to spinal cord injury, Alzheimer's disease, and coronavirus disease 2019 (COVID-19) .
    Withanoside IV
  • HY-135456
    Ro4368554

    		5-HT Receptor Neurological Disease
    Ro4368554 is a brain-penetrant and selective 5-HT6 antagonist that reverses memory deficits induced by scopolamine and tryptophan depletion. Ro4368554 can be utilized in research related to memory deficits .
    Ro4368554
  • HY-105435
    FR121196

    		mAChR Dopamine Receptor Neurological Disease
    FR121196 is a cognitive enhancer, and ameliorates Scopolamine (HY-N0296)-induced memory deficit. FR121196 is an antidementia compound .
    FR121196
  • HY-W003576
    ACHE-IN-38 hydrochloride

    		Cholinesterase (ChE) Neurological Disease
    ACHE-IN-38 hydrochloride (Compound 13b) inhibits the metabolic breakdown of the neurotransmitter acetylcholine (ACh) by the enzyme acetylcholinesterase (AChE) and hence alleviates memory deficits in patients with Alzheimer’s Disease by potentiating cholinergic transmission .
    ACHE-IN-38 hydrochloride
  • HY-N0459R
    3,5-O-Dicaffeoylquinic acid (Standard)

    		Reference Standards Others Neurological Disease
    3,5-O-Dicaffeoylquinic acid (Standard) is the analytical standard of 3,5-O-Dicaffeoylquinic acid. This product is intended for research and analytical applications. 3,5-O-Dicaffeoylquinic acid reverses Trimethyltin-induced learning and memory deficits .
    3,5-O-Dicaffeoylquinic acid (Standard)
  • HY-143464
    BChE-IN-4

    		Cholinesterase (ChE) Neurological Disease
    BChE-IN-4 is a potent and cross the blood-brain barrier BChE inhibitor. BChE-IN-4 attenuates learning and memory deficits caused by cholinergic deficit in mouse model. BChE-IN-4 has the potential for the research of alzheimer’s disease .
    BChE-IN-4
  • HY-116881
    SCH 57790

    		mAChR Neurological Disease
    SCH 57790 is a selective antegonist for muscarinic M2 receptor, which increases acetylcholine release, and thus improves cognitive performance. SCH 57790 reverses Scopolamine (HY-N0296)-induced memory deficits in mice, without significant toxicity (100 mg/kg).
    SCH 57790
  • HY-17460AR
    Garenoxacin Mesylate hydrate (Standard)

    BMS284756 Mesylate hydrate (Standard)

    		 Reference Standards Bacterial Topoisomerase DNA/RNA Synthesis Antibiotic Infection
    ACHE-IN-38 (hydrochloride) (Standard) is the analytical standard of ACHE-IN-38 (hydrochloride). This product is intended for research and analytical applications. ACHE-IN-38 hydrochloride (Compound 13b) inhibits the metabolic breakdown of the neurotransmitter acetylcholine (ACh) by the enzyme acetylcholinesterase (AChE) and hence alleviates memory deficits in patients with Alzheimer’s Disease by potentiating cholinergic transmission .
    Garenoxacin Mesylate hydrate (Standard)
  • HY-U00085
    Itameline

    RU 47213

    		 Cholinesterase (ChE) Neurological Disease
    Itameline (RU 47213) is a prodrug with oral and long-lasting cholinergic activity. Itameline is a novel tetrahydropyridine-oxime that is cleaved in vivo to form an active metabolite, RU 35963. RU 35963 is a muscarinic receptor agonist that is nonselective with respect to receptor subtypes. Itameline possesses the capacity to reduce memory deficits induced by an impairment of cholinergic transmission in the rat .
    Itameline
  • HY-W003576R
    ACHE-IN-38 hydrochloride (Standard)

    		Cholinesterase (ChE) Reference Standards Neurological Disease
    ACHE-IN-38 (hydrochloride) (Standard) is the analytical standard of ACHE-IN-38 (hydrochloride). This product is intended for research and analytical applications. ACHE-IN-38 hydrochloride (Compound 13b) inhibits the metabolic breakdown of the neurotransmitter acetylcholine (ACh) by the enzyme acetylcholinesterase (AChE) and hence alleviates memory deficits in patients with Alzheimer’s Disease by potentiating cholinergic transmission .
    ACHE-IN-38 hydrochloride (Standard)
  • HY-115910
    Y13g

    		Cholinesterase (ChE) Interleukin Related Neurological Disease
    Y13g is the potent inhibitor of both AChE and IL-6. Interleukin-6 (IL-6) and acetylcholinesterase (AChE) are two important targets implicated in progression of Alzheimer's Disease (AD). Y13g reverses the STZ (HY-13753)-induced memory deficit, and shows histopathology similarly as in normal animals .
    Y13g
  • HY-P3355
    p-fin4

    		iGluR Neurological Disease
    p-fin4 is a peptide inhibitor of STEP Phosphatase-GluA2 AMPA receptor interaction with a Ki of 0.4 μM. p-fin4 restores the memory deficits and displays anxiolytic and antidepressant effects in a scopolamine-treated rat model. p-fin4 is a promising lead compound for novel cognitive enhancers and/or behavioral modulators .
    p-fin4
  • HY-155572
    Nrf2 activator-8

    		Keap1-Nrf2 Inflammation/Immunology
    Nrf2 activator-8 (compound 10e) is a Nrf2 activator (EC50=37.9 nM). Nrf2 activator-8 exhibits remarkable antioxidant and anti-inflammatory effects in BV-2 microglial cells. Nrf2 activator-8 can significantly restore spatial memory deficits in a mouse model of lipopolysaccharide (LPS)-induced neuroinflammation .
    Nrf2 activator-8
  • HY-158659
    TG11-77 hydrochloride

    		Prostaglandin Receptor Neurological Disease Inflammation/Immunology
    TG11-77 hydrochloride is a potent, selective, orally active and brain permeant EP2 antagonist, with a KB of 9.7 nM. TG11-77 hydrochloride inhibits PGE2-induced human EP2 receptor activation. TG11-77 hydrochloride exhibits anti-inflammatory activity. TG11-77 hydrochloride reduces delayed mortality and memory deficit .
    TG11-77 hydrochloride
  • HY-B1266R
    Physostigmine salicylate (Standard)

    Eserine salicylate (Standard)

    		 Reference Standards Cholinesterase (ChE) Neurological Disease
    Physostigmine (salicylate) (Standard) is the analytical standard of Physostigmine (salicylate). This product is intended for research and analytical applications. Physostigmine salicylate (Eserine salicylate) is a reversible acetylcholinesterase (AChE) inhibitor. Physostigmine salicylate crosses the blood-brain barrier and stimulates central cholinergic neurotransmission. Physostigmine salicylate can reverse memory deficits in transgenic mice with Alzheimer's disease. Physostigmine salicylate is also an antidote for anticholinergic poisoning .
    Physostigmine salicylate (Standard)
  • HY-108157
    A-72055

    		mAChR Neurological Disease
    A-72055 is a partial agonist of muscarinic receptors. A-72055 has binding activity to both M1 and M2 receptors, with Ki values of 32 nM and 30 nM, respectively. A-72055 can enhance cognitive function and improve learning and memory deficits. A-72055 has better security. A-72055 can be used for research on neurological disorders such as cognitive impairment .
    A-72055
  • HY-P3354
    p3Ysh-3

    		iGluR Neurological Disease
    p3Ysh-3 is a peptide inhibitor of STEP Phosphatase-GluA2 AMPA receptor interaction with a Ki of 1.09 μM. p3Ysh-3 restores the memory deficits and displays anxiolytic and antidepressant effects in a scopolamine-treated rat model. p3Ysh-3 is a promising lead compound for novel cognitive enhancers and/or behavioral modulators .
    p3Ysh-3
  • HY-10295R
    SB 202190 (Standard)

    		Organoid Reference Standards p38 MAPK Autophagy Apoptosis Neurological Disease Cancer
    SB 202190 (Standard) is the analytical standard of SB 202190. This product is intended for research and analytical applications. SB 202190 is a selective p38 MAP kinase inhibitor with IC50s of 50 nM and 100 nM for p38α and p38β2, respectively. SB 202190 binds to the ATP pocket of the active recombinant human p38 kinase with a Kd of 38 nM. SB 202190 has anti-cancer activity and rescued memory deficits . SB202190 induces autophagy .
    SB 202190 (Standard)
  • HY-155330
    PZ-1922

    		5-HT Receptor Monoamine Oxidase Neurological Disease
    PZ-1922 (Compound 16) is a BBB-penetrable 5-HT6R/5-HT3R antagonist (Ki: 17 nM, 0.45 nM for 5-HT6R/5-HT3R respectively). PZ-1922 reversibly inhibits MAO-B (pIC50: 8.93). PZ-1922 reverses Scopolamine (SCOP) (HY-N0296) induced memory deficits in the novel object recognition (NOR) test in rats. PZ-1922 prevents Aβ-induced memory decline in the T-maze test .
    PZ-1922

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: